Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.
By J. Mchutchison, E. Lawitz, M. Shiffman, A. Muir, G. Galler, J. McCone, L. Nyberg, William M. Lee, R. Ghalib, E. Schiff and 10 more. New England Journal of Medicine, 2009
1,263 citations recorded by the source corpus.
Subfields: Epidemiology, Hepatology, Immunology
View Paper: https://www.semanticscholar.org/paper/fbf130e1438bd263094054aeea0a3b23b7ca50ad
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Epidemiology
In Hepatology
Citations in the corpus
- Telaprevir for retreatment of HCV infection. (2011, background): “Injury, poisoning, or procedural complication 1 (<1) 3 (1) 0”
- Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection (2011, neutral): “03 Grade 4: <500 per mm3 3 (4) 10 (6) 11 (7) 0.”
- Next generation disparities in human genomics: concerns and remedies. (2009, background): “For example, treatment of chronic hepatitis C infection has a lower chance of success in African-Americans than in European-Americans [ 16 ].”
- EASL Clinical Practice Guidelines: management of hepatitis C virus infection. (2011, background): “A large-scale post-approval US trial comparing various schedules of administration of pegylated IFN-a2a and IFN-a2b with ribavirin in patients infected with HCV genotype 1 showed no significant difference between the tested strategies [37].”
- Boceprevir for Untreated Chronic HCV Genotype 1 Infection (2011, neutral): “Decreased by <1 log10 IU/ml 3/62 (5) 21/73 (29) <0.”